AI-generated analysis. Always verify with the original filing.
Lixte Biotechnology Holdings, Inc. entered into an Allocation Deed and Consultancy Agreement on February 12 and 13, 2026, respectively, with Liora Technologies Europe Ltd. and Sidney Braun, appointing him as Liora's board member and CEO with specified compensation and a 20% net purchase price allocation upon sale. The company issued a press release on February 18, 2026, announcing the appointment.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On February 12, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Liora Technologies Europe Ltd, a subsidia
disclosure, including Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, except
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed herewith. Exhibit Number Description 10.1 Allocation Deed dated February 12, 20
Sidney Braun
Effective: 2026-02-13
Material Agreement